in

Abbott Receives EUA for Rapid Point-of-Care COVID-19 Diagnostic

technician inserts sample swab in lab machine on table
Testing being performed on Abbott’s ID NOW. Credit: Abbott

Abbott today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company’s ID NOW™ platform, providing rapid results in a wide range of healthcare settings such as physicians’ offices, urgent care clinics and hospital emergency departments.

“The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Robert B. Ford, Abbott’s president and chief operating officer. “With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.

The Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott m2000™ RealTime SARS-CoV-2 EUA test, which runs on the m2000™ RealTime System located in hospital and reference labs around the world. Between the two platforms, Abbott expects to produce about 5 million tests per month.

DoD Looks to Panther Fusion System for High-Throughput Coronavirus Diagnostics

CBRN Medical Countermeasures - Innovation Incubators

Mapping Risks to the Drug Supply Chain During COVID-19 Pandemic: Critical Shortages Likely in U.S.